[A24-12] Elranatamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 18.07.2024
Project no.:
A24-12
Commission:
Commission awarded on 15.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-12_en
| Project no. | Title | Status |
|---|---|---|
| G24-11 | Elranatamab (multiple myeloma) - Addendum to Project A24-12 | Commission completed |
Federal Joint Committee (G-BA)
2024-07-18 A G-BA decision was published.